Re: Prostate Cancer in Men Using Testosterone Supplementation

Abstract

No AccessJournal of UrologyLetter to the Editor/Errata1 Apr 2006Re: Prostate Cancer in Men Using Testosterone SupplementationF. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove Abraham Morgentaler, Ernani L. Rhoden, Al Baha Barqawi, and E. David Crawford Abraham MorgentalerAbraham Morgentaler Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts More articles by this author , Ernani L. RhodenErnani L. Rhoden Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts More articles by this author , Al Baha BarqawiAl Baha Barqawi Section on Urological Oncology, University of Colorado Health Sciences Center, Anschutz Cancer Pavillion, 1665 N. Ursula St., Suite 1004, P. O. Box 6510, Mail Stop F-710, Aurora, Colorado 80010 More articles by this author , and E. David CrawfordE. David Crawford Section on Urological Oncology, University of Colorado Health Sciences Center, Anschutz Cancer Pavillion, 1665 N. Ursula St., Suite 1004, P. O. Box 6510, Mail Stop F-710, Aurora, Colorado 80010 More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)00691-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail References 1 : Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med2004; 350: 482. Google Scholar 2 : Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol2003; 170: 2348. Link, Google Scholar 3 : Hormones and prostate cancer: what’s next?. Epidemiol Rev2001; 23: 42. Google Scholar 4 : Occult prostate cancer in men with low serum testosterone levels. ?? JAMA1996; 276: 1904. Google Scholar 5 : Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population. Br J Urol1996; 77: 433. Google Scholar 6 : Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst1998; 90: 756. Google Scholar 7 : Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate1995; 27: 25. Google Scholar 8 : Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging2000; 17: 431. Google Scholar 9 : Serum testosterone levels in African-American and white men undergoing prostate biopsy. ?? Urology1999; 54: 1035. Google Scholar 10 : Is low serum free testosterone a marker for high grade prostate cancer?. J Urol2000; 163: 824. Link, Google Scholar 11 : Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol2003; 169: 1670. Link, Google Scholar 12 : Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol2005; 47: 308. Google Scholar 13 : Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst1997; 89: 385. Google Scholar 14 : Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab2001; 86: 1341. Google Scholar 15 : Interrelationships between plasma testosterone, sex hormone binding globulin, insulin-like growth factor-1, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev2003; 12: 309. Google Scholar 16 : Testosterone and Aging. Washington, D. C: National Academies Press2004: 115. Google Scholar 17 : Results of prostate biopsy in men with low serum testosterone. J Urol2003; 169: 119. abstract 461. Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetails Volume 175Issue 4April 2006Page: 1572-1574 Advertisement Copyright & Permissions© 2006 by American Urological AssociationMetricsAuthor Information Abraham Morgentaler Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts More articles by this author Ernani L. Rhoden Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts More articles by this author Al Baha Barqawi Section on Urological Oncology, University of Colorado Health Sciences Center, Anschutz Cancer Pavillion, 1665 N. Ursula St., Suite 1004, P. O. Box 6510, Mail Stop F-710, Aurora, Colorado 80010 More articles by this author E. David Crawford Section on Urological Oncology, University of Colorado Health Sciences Center, Anschutz Cancer Pavillion, 1665 N. Ursula St., Suite 1004, P. O. Box 6510, Mail Stop F-710, Aurora, Colorado 80010 More articles by this author Expand All Advertisement PDF DownloadLoading ...